At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 45 enrolled
Drug / intervention
VarilrixTMbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III, Open-label, Multi-centre Study to Assess the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Live Attenuated Varicella Vaccine (VarilrixTM), Given as a Primary Vaccination at 4.5 Months and 6.5 Months Post-transplantation, in Autologous Stem Cell/ Bone Marrow Transplant Recipients Aged 18 Years and Older.
In Brief
A Phase 2 clinical trial evaluating VarilrixTM for Varicella. Completed, enrolled 45 participants across 3 sites.
Detailed Summary
This study aims to assess the immunogenicity and safety of varicella vaccination in a population of autologous peripheral stem cell/ bone marrow transplantation recipients who have reached at least four months post-transplantation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVaricella
CountriesAustralia
Collaborators--
Timeline
Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2003
Primary CompletionSep 2007
First PostedNov 2008
TodayJul 2026
First PostedNov 18, 2008
Enrollment StartSep 8, 2003
Primary CompletionSep 10, 2007
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 17.6 years ago
Interventions
VarilrixTMbiological
Subcutaneous injection, 2 doses, in the deltoid region of the non-dominant upper arm.